Abivax’s shares surged in Paris trading earlier Monday as speculation mounted over a possible takeover of the French company following a report in La Lettre.
The French finance ministry told Bloomberg that it hasn’t received a dossier for investment screening from Eli Lilly and is not in contact with the company. In the case of strategic pharmaceutical companies, such a request for ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.